The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

maintenance regimen of Leqembi ® (lecanemab-irmb) for early Alzheimer disease. Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble and insoluble ...

1,2,3 Only LEQEMBI works to fight AD in two ways: continuously clearing protofibrils and rapidly clearing plaque. This is important because with continuous administration, LEQEMBI clears highly ...